Literature DB >> 1979923

Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

C G Regardh1, A Heggelund, K Kylberg-Hanssen, P Lundborg.   

Abstract

The pharmacokinetics of pafenolol were evaluated in 12 healthy subjects after administration of three single IV doses (5, 10, and 20 mg) and three oral single doses (25, 50, and 100 mg). The drug was discontinuously absorbed. A first peak was observed 0.5 to 1.5 h after dosing and a second higher maximum concentration was noted 3 to 5 h after the administration in the majority of the experiments. The mean systemic availability increased from 27 +/- 5 per cent for the oral 25 mg dose to 46 +/- 5 per cent for the 100 mg dose, i.e., an increase of about 70 per cent (p less than 0.05). The half-life of distribution varied between 5 and 6 min and the apparent volume of distribution (Vz) was about 1.11 kg-1. The distribution was linear in the IV dose range studied. Total body clearance was about 300 ml min-1. About 50 per cent of the systemically available dose was excreted unchanged via the kidneys. Total body clearance decreased by about 13 per cent (p less than 0.05) by increasing the dose from 5 to 20 mg IV possibly because of reduced renal elimination. Mean terminal t1/2 of the IV dose was approximately 3.5 h. The corresponding t1/2 of the oral dose was approximately 6 h indicating absorption rate-limited kinetics of the oral dose.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979923     DOI: 10.1002/bdd.2510110706

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Model analysis of the concentration-dependent permeability of P-gp substrates.

Authors:  Tatsuhiko Tachibana; Satoshi Kitamura; Motohiro Kato; Tetsuya Mitsui; Yoshiyuki Shirasaka; Shinji Yamashita; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2010-02-05       Impact factor: 4.200

3.  Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

4.  Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

5.  Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000.

Authors:  H Lennernäs; C G Regårdh
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

6.  Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

Authors:  E Lipka; I D Lee; P Langguth; H Spahn-Langguth; E Mutschler; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

7.  Gastrointestinal transit and distribution of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

Review 8.  Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models.

Authors:  David Dahlgren; Erik Sjögren; Hans Lennernäs
Journal:  ADMET DMPK       Date:  2020-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.